Solid Tumors — Expanded Access Programs
Overview
Right2Hope maintains a directory of 36 expanded access programs, clinical trials, and compassionate use pathways listed for Solid Tumors. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with solid tumors programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 16 programs are currently active or recruiting, with the remaining 20 in other lifecycle stages. Sponsors actively running programs in this area include Pfizer, Hoffmann-La Roche, EMD Serono Research & Development Institute, Inc., Incyte Corporation, Jacobio Pharmaceuticals Co., Ltd., and others.
By recruiting status
Snapshot of where every Solid Tumors program currently sits in its lifecycle.
- Active / Recruiting16
- Inactive20
Top sponsors
Organisations running the most Solid Tumors programs in the directory.
- Pfizer4 programs
- Hoffmann-La Roche3 programs
- EMD Serono Research & Development Institute, Inc.2 programs
- Incyte Corporation2 programs
- Jacobio Pharmaceuticals Co., Ltd.2 programs
- Merck Sharp & Dohme LLC2 programs
- ABL Bio, Inc.1 program
- Amgen1 program
- Apollomics Inc.1 program
- BioInvent International AB1 program
Solid Tumors programs (36)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study for Long-Term Treatment of Cancer Patients Who Previously Participated in Adagrasib Trials — Mirati Therapeutics Inc.
- Study on BMS-986504 Alone and with Other Treatments for Advanced Solid Tumors with MTAP Deletion — Bristol-Myers Squibb
- Study on ZL-1310 for Patients with Certain Advanced Solid Tumors — Zai Lab (Shanghai) Co., Ltd.
- Study on Chemotherapy With or Without INCB161734 for Untreated KRAS G12D-Mutated Metastatic Pancreatic Cancer — Incyte Corporation
- Study on INCB177054 for Patients with Advanced or Metastatic Solid Tumors — Incyte Corporation
- Study Using White Blood Cells from Healthy Donors to Treat Solid Cancers — Dipnarine Maharaj
- Study on ABL103 and Pembrolizumab, With or Without Taxane, for Advanced or Metastatic Solid Tumors — ABL Bio, Inc.
- Avelumab Program Rollover Study — EMD Serono Research & Development Institute, Inc.
- Continued Access Study for Patients Benefiting from Avelumab in Closing Pfizer-Sponsored Studies — Pfizer
- Study on DB-1311 Combined with BNT327 or DB-1305 for Advanced or Metastatic Solid Tumors — DualityBio Inc.
- Study on the Safety of GEN1046 in Patients with Malignant Solid Tumors — Genmab
- Study on ASTX660 for Patients with Advanced Solid Tumors and Lymphomas — Taiho Oncology, Inc.
- Phase II Study of SAR444881 and Cemiplimab in Solid Tumors — M.D. Anderson Cancer Center
- Study on Anti-CEACAM5 ADC M9140 for Advanced Solid Tumors (PROCEADE PanTumor) — EMD Serono Research & Development Institute, Inc.
- Study on Entrectinib for Children and Teens with Advanced or Hard-to-Treat Solid or Brain Tumors — Hoffmann-La Roche
- Study on Palbociclib with Chemotherapy for Children and Young Adults with Hard-to-Treat Solid Tumors — Pfizer
- Pilot Study on Thermodox and MR-HIFU for Treating Relapsed Solid Tumors — Children's National Research Institute
- Study on Bemarituzumab for Solid Tumors with High FGFR2b Levels — Amgen
- A Study of DF6002 Alone and in Combination With Nivolumab — Dragonfly Therapeutics
- Study on LY2880070 for Patients with Advanced or Metastatic Cancer — Esperas Pharma Inc.
- Study on the Safety and Effectiveness of CFT1946 Alone and in Combination for BRAF V600 Mutant Solid Tumors — C4 Therapeutics, Inc.
- Study on the Safety and Effects of Eflapegrastim in Children with Solid Tumors or Lymphomas Undergoing Chemotherapy — Spectrum Pharmaceuticals, Inc
- Study on the Safety and Effects of PF-07220060 and PF-07104091 in People with Breast Cancer and Other Solid Tumors — Pfizer
- Study on APL-101 for Treating Advanced Solid Tumors with Specific Genetic Changes — Apollomics Inc.
- Study on BI-1910 Alone and with Pembrolizumab for Treating Advanced Solid Tumors — BioInvent International AB
- Brightline-2: Testing Brigimadlin (BI 907828) for Cancer in the Biliary Tract, Pancreas, Lung, or Bladder — Boehringer Ingelheim
- Study on a New PD1-LAG3 Antibody for Patients with Advanced or Metastatic Solid Tumors — Hoffmann-La Roche
- Study on Revumenib for Patients with Colorectal Cancer and Other Solid Tumors — Syndax Pharmaceuticals
- Study on JAB-2485 for Adults with Advanced Solid Tumors — Jacobio Pharmaceuticals Co., Ltd.
- Study on JAB-30355 for Adults with Advanced Solid Tumors with TP53 Y220C Mutation — Jacobio Pharmaceuticals Co., Ltd.
- Long-term Safety and Effectiveness Study for Patients with Advanced Tumors on Pembrolizumab Treatment — Merck Sharp & Dohme LLC
- Study on S-531011 Alone and with an Immune Checkpoint Inhibitor for Advanced or Metastatic Solid Tumors — Shionogi
- Study on Olaparib and Pembrolizumab for Treating Advanced Cancers with Specific Genetic Mutations — Merck Sharp & Dohme LLC
- Study of ORIC-114 for Patients with Advanced Solid Tumors with EGFR or HER2 Changes — ORIC Pharmaceuticals
- The FLOTILLA Study: Continued Access to Encorafenib and Binimetinib for Participants from Previous Trials — Pfizer
- TAPISTRY Study: Personalized Immunotherapy and Targeted Treatment for Advanced Solid Tumors — Hoffmann-La Roche
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Solid Tumors to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.